nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

12.10.2022 | Original Article

Prognostic value of fibroblast activation protein expressing tumor volume calculated from [⁶⁸ Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma

verfasst von: Liang Zhao, Yizhen Pang, Shanyu Chen, Jianhao Chen, Yimin Li, Yifeng Yu, Chunbin Huang, Long Sun, Hua Wu, Haojun Chen, Qin Lin

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

This study aimed to investigate the prognostic value of semiquantitative parameters derived from [⁶⁸ Ga]Ga-fibroblast activation protein inhibitor (FAPI) PET/CT for patients with esophageal squamous cell carcinoma (ESCC) treated with definitive chemoradiotherapy.

Methods

We conducted a retrospective analysis on patients from a prospective parent study (NCT04416165). A total of 45 patients with locally advanced ESCC who underwent [⁶⁸ Ga]Ga-FAPI from December 2019 to March 2021 were included. The maximum standard uptake value (SUVmax), gross tumor volume (GTV), and total lesion-FAPI (TL-FAPI) of the primary tumor were calculated from the corresponding PET/CT image. Unpaired parameters were compared using Student’s t test or the Mann–Whitney U test. Paired parameters were compared using the paired t test or the Wilcoxon matched-pairs signed-rank test. Kaplan–Meier curves were generated to calculate progression-free survival (PFS) and overall survival (OS) rates, and Cox regression analysis was performed to determine which PET/CT parameters were prognostic factors for PFS and/or OS.

Results

Thirty-four of the 45 patients met the criteria, and the median follow-up time was 24 months (16–29 months). SUVmax-FAPI, GTV_FAPI, and TL-FAPI in patients with stage T4 tumors were significantly higher than those in patients with stage T2/T3 tumors (all P < 0.01). In the univariate Cox regression analysis, T stage, N stage, GTV_FAPI, and TL-FAPI were associated with PFS, and T stage, GTV_FAPI, and TL-FAPI were associated with OS. Upon multivariable analysis, GTV_FAPI was an independent prognostic factor for both PFS (hazard ratio (HR), 5.76; 95% confidence interval (CI), 2.13–15.57, P = 0.001) and OS (HR, 4.96; 95% CI, 2.55–18.79, P = 0.001).

Conclusion

This pilot study revealed that [⁶⁸ Ga]Ga-FAPI PET/CT may have prognostic value for patients with ESCC treated with definitive chemoradiotherapy. It may aid in personalized patient management by steering treatment modifications before therapy. Prospective studies with larger samples and longer observation periods are needed.

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.CrossRef

Abnet CC, Arnold M, Wei WQ. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology. 2018;154(2):360–73. https://doi.org/10.1053/j.gastro.2017.08.023.CrossRef

Collaborators GBDOC. The global, regional, and national burden of oesophageal cancer and its attributable risk factors in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(6):582–97. https://doi.org/10.1016/S2468-1253(20)30007-8.

van Workum F, Verstegen MHP, Klarenbeek BR, Bouwense SAW, van Berge Henegouwen MI, Daams F, et al. Intrathoracic vs cervical anastomosis after totally or hybrid minimally invasive esophagectomy for esophageal cancer: a randomized clinical trial. JAMA Surg. 2021;156(7):601–10. https://doi.org/10.1001/jamasurg.2021.1555.CrossRef

Sudo K, Xiao L, Wadhwa R, Shiozaki H, Elimova E, Taketa T, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol. 2014;32(30):3400–5. https://doi.org/10.1200/JCO.2014.56.7156.CrossRef

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7. https://doi.org/10.1001/jama.281.17.1623.CrossRef

Mendelsohn J. Personalizing oncology: perspectives and prospects. J Clin Oncol. 2013;31(15):1904–11. https://doi.org/10.1200/JCO.2012.45.3605.CrossRef

Rice TW, Apperson-Hansen C, DiPaola LM, Semple ME, Lerut TE, Orringer MB, et al. Worldwide Esophageal Cancer Collaboration: clinical staging data. Dis Esophagus. 2016;29(7):707–14. https://doi.org/10.1111/dote.12493.CrossRef

Mo R, Chen C, Pan L, Yu A, Wang D, Wang T. Is the new distribution of early esophageal adenocarcinoma stages improving the prognostic prediction of the 8(th) edition of the TNM staging system for esophageal cancer? J Thorac Dis. 2018;10(9):5192–8. https://doi.org/10.21037/jtd.2018.08.98.CrossRef

10.

Xu L, Ge X, Sun N, Liu X. Dynamic contrast-enhanced MRI histogram parameters predict progression-free survival in patients with advanced esophageal squamous carcinoma receiving concurrent chemoradiotherapy. Acta Radiol. 2020;61(10):1316–25. https://doi.org/10.1177/0284185120903139.CrossRef

11.

Xie Y, Wang Q, Cao B, Lv J, Wang Y, Wu L, et al. Textural features based enhanced contrast CT images predicts prognosis to concurrent chemoradiotherapy in stage III esophageal squamous cell cancer. Cancer Biomark. 2020;27(3):325–33. https://doi.org/10.3233/CBM-190586.CrossRef

12.

Yip C, Landau D, Kozarski R, Ganeshan B, Thomas R, Michaelidou A, et al. Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy. Radiology. 2014;270(1):141–8. https://doi.org/10.1148/radiol.13122869.CrossRef

13.

Mantziari S, Pomoni A, Prior JO, Winiker M, Allemann P, Demartines N, et al. (18)F-FDG PET/CT-derived parameters predict clinical stage and prognosis of esophageal cancer. BMC Med Imaging. 2020;20(1):7. https://doi.org/10.1186/s12880-019-0401-x.CrossRef

14.

Lemarignier C, Di Fiore F, Marre C, Hapdey S, Modzelewski R, Gouel P, et al. Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41(11):2008–16. https://doi.org/10.1007/s00259-014-2839-y.CrossRef

15.

Hofheinz F, Li Y, Steffen IG, Lin Q, Lili C, Hua W, et al. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2019;46(7):1485–94. https://doi.org/10.1007/s00259-019-04307-6.CrossRef

16.

Takahashi N, Umezawa R, Takanami K, Yamamoto T, Ishikawa Y, Kozumi M, et al. Whole-body total lesion glycolysis is an independent predictor in patients with esophageal cancer treated with definitive chemoradiotherapy. Radiother Oncol. 2018;129(1):161–5. https://doi.org/10.1016/j.radonc.2017.10.019.CrossRef

17.

Zhao L, Chen J, Pang Y, Fu K, Shang Q, Wu H, et al. Fibroblast activation protein-based theranostics in cancer research: a state-of-the-art review. Theranostics. 2022;12(4):1557–69. https://doi.org/10.7150/thno.69475.CrossRef

18.

Zhao L, Chen S, Lin L, Sun L, Wu H, Lin Q, et al. [(68)Ga]Ga-DOTA-FAPI-04 improves tumor staging and monitors early response to chemoradiotherapy in a patient with esophageal cancer. Eur J Nucl Med Mol Imaging. 2020;47(13):3188–9. https://doi.org/10.1007/s00259-020-04818-7.CrossRef

19.

Liu Q, Shi S, Xu X, Yu X, Song S. The superiority of [(68)Ga]-FAPI-04 over [(18)F]-FDG PET/CT in imaging metastatic esophageal squamous cell carcinoma. Eur J Nucl Med Mol Imaging. 2021;48(4):1248–9. https://doi.org/10.1007/s00259-020-04997-3.CrossRef

20.

Ristau J, Giesel FL, Haefner MF, Staudinger F, Lindner T, Merkel A, et al. Impact of primary staging with fibroblast activation protein specific enzyme inhibitor (FAPI)-PET/CT on radio-oncologic treatment planning of patients with esophageal cancer. Mol Imaging Biol. 2020;22(6):1495–500. https://doi.org/10.1007/s11307-020-01548-y.CrossRef

21.

Zhao L, Chen S, Chen S, Pang Y, Dai Y, Hu S, et al. (68)Ga-fibroblast activation protein inhibitor PET/CT on gross tumour volume delineation for radiotherapy planning of oesophageal cancer. Radiother Oncol. 2021;158:55–61. https://doi.org/10.1016/j.radonc.2021.02.015.CrossRef

22.

Li Y, Hofheinz F, Furth C, Lili C, Hua W, Ghadjar P, et al. Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 2018;45(10):1752–61. https://doi.org/10.1007/s00259-018-3996-1.CrossRef

23.

Cao Q, Li Y, Li Z, An D, Li B, Lin Q. Development and validation of a radiomics signature on differentially expressed features of (18)F-FDG PET to predict treatment response of concurrent chemoradiotherapy in thoracic esophagus squamous cell carcinoma. Radiother Oncol. 2020;146:9–15. https://doi.org/10.1016/j.radonc.2020.01.027.CrossRef

24.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRef

25.

Chen H, Zhao L, Ruan D, Pang Y, Hao B, Dai Y, et al. Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET/CT in patients presenting with inconclusive [(18)F]FDG PET/CT findings. Eur J Nucl Med Mol Imaging. 2021;48(1):73–86. https://doi.org/10.1007/s00259-020-04940-6.CrossRef

26.

Zhao L, Zhuang Y, Fu K, Chen P, Wang Y, Zhuo J, et al. Usefulness of [(18)F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2020. https://doi.org/10.1007/s00259-019-04654-4.CrossRef

27.

Schmidkonz C, Rauber S, Atzinger A, Agarwal R, Gotz TI, Soare A, et al. Disentangling inflammatory from fibrotic disease activity by fibroblast activation protein imaging. Ann Rheum Dis. 2020;79(11):1485–91. https://doi.org/10.1136/annrheumdis-2020-217408.CrossRef

28.

Zhao L, Pang Y, Zheng H, Han C, Gu J, Sun L, et al. Clinical utility of [(68)Ga]Ga-labeled fibroblast activation protein inhibitor (FAPI) positron emission tomography/computed tomography for primary staging and recurrence detection in nasopharyngeal carcinoma. Eur J Nucl Med Mol Imaging. 2021;48(11):3606–17. https://doi.org/10.1007/s00259-021-05336-w.CrossRef

29.

Jun S, Park JG, Seo Y. Accurate FDG PET tumor segmentation using the peritumoral halo layer method: a study in patients with esophageal squamous cell carcinoma. Cancer Imaging. 2018;18(1):35. https://doi.org/10.1186/s40644-018-0169-1.CrossRef

30.

Li YM, Lin Q, Zhao L, Wang LC, Sun L, Dai MM, et al. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients. Asian Pac J Cancer Prev. 2014;15(3):1369–73. https://doi.org/10.7314/apjcp.2014.15.3.1369.CrossRef

31.

Hong SJ, Kim TJ, Nam KB, Lee IS, Yang HC, Cho S, et al. New TNM staging system for esophageal cancer: what chest radiologists need to know. Radiographics. 2014;34(6):1722–40. https://doi.org/10.1148/rg.346130079.CrossRef

32.

Veuillez V, Rougier P, Seitz JF. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of oesophageal cancer. Best Pract Res Clin Gastroenterol. 2007;21(6):947–63. https://doi.org/10.1016/j.bpg.2007.10.005.CrossRef

33.

Eskian M, Alavi A, Khorasanizadeh M, Viglianti BL, Jacobsson H, Barwick TD, et al. Effect of blood glucose level on standardized uptake value (SUV) in (18)F-FDG PET-scan: a systematic review and meta-analysis of 20,807 individual SUV measurements. Eur J Nucl Med Mol Imaging. 2019;46(1):224–37. https://doi.org/10.1007/s00259-018-4194-x.CrossRef

34.

Wikberg ML, Edin S, Lundberg IV, Van Guelpen B, Dahlin AM, Rutegard J, et al. High intratumoral expression of fibroblast activation protein (FAP) in colon cancer is associated with poorer patient prognosis. Tumour Biol. 2013;34(2):1013–20. https://doi.org/10.1007/s13277-012-0638-2.CrossRef

35.

Yang ZT, Yeo SY, Yin YX, Lin ZH, Lee HM, Xuan YH, et al. Tenascin-C, a prognostic determinant of esophageal squamous cell carcinoma. PLoS ONE. 2016;11(1): e0145807. https://doi.org/10.1371/journal.pone.0145807.CrossRef

36.

Zou B, Liu X, Zhang B, Gong Y, Cai C, Li P, et al. The expression of FAP in hepatocellular carcinoma cells is induced by hypoxia and correlates with poor clinical outcomes. J Cancer. 2018;9(18):3278–86. https://doi.org/10.7150/jca.25775.CrossRef

37.

Higashino N, Koma YI, Hosono M, Takase N, Okamoto M, Kodaira H, et al. Fibroblast activation protein-positive fibroblasts promote tumor progression through secretion of CCL2 and interleukin-6 in esophageal squamous cell carcinoma. Lab Invest. 2019;99(6):777–92. https://doi.org/10.1038/s41374-018-0185-6.CrossRef

38.

Augoff K, Hryniewicz-Jankowska A, Tabola R, Czapla L, Szelachowski P, Wierzbicki J, et al. Upregulated expression and activation of membraneassociated proteases in esophageal squamous cell carcinoma. Oncol Rep. 2014;31(6):2820–6. https://doi.org/10.3892/or.2014.3162.CrossRef

39.

Sardaro A, Ferrari C, Carbonara R, Altini C, Lavelli V, Rubini G. Synergism between immunotherapy and radiotherapy in esophageal cancer: an overview of current knowledge and future perspectives. Cancer Biother Radiopharm. 2021;36(2):123–32. https://doi.org/10.1089/cbr.2020.3643.CrossRef

Titel: Prognostic value of fibroblast activation protein expressing tumor volume calculated from [68 Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma
verfasst von: Liang Zhao
Yizhen Pang
Shanyu Chen
Jianhao Chen
Yimin Li
Yifeng Yu
Chunbin Huang
Long Sun
Hua Wu
Haojun Chen
Qin Lin
Publikationsdatum: 12.10.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 2/2023
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05989-1

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Prognostic value of fibroblast activation protein expressing tumor volume calculated from [⁶⁸ Ga]Ga-FAPI PET/CT in patients with esophageal squamous cell carcinoma

Abstract

Background

Methods

Results

Conclusion

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2023

Feasibility of using abbreviated scan protocols with population-based input functions for accurate kinetic modeling of [18F]-FDG datasets from a long axial FOV PET scanner

First-in-human evaluation of [18F]CETO: a novel tracer for adrenocortical tumours

Cancer photodynamic therapy with chlorin e6-loaded, goat milk-derived extracellular vesicles: [18F]FDG lights up the way

In memoriam

Positive opinion of the French National Authority for Health on the reimbursement of amyloid tracer (Flutemetamol)

Enhanced antitumor immune responses via a new agent [131I]-labeled dual-target immunosuppressant